USFDA has completed inspection of the facility in Gagillapur located in Hyderabad, Telangana, India on February 14, 2020, with two observations. Granules India will respond to these observations within the stipulated time.
“We successfully completed an FDA audit with two observations, which are being addressed and will respond to the FDA within the stipulated time. These observations will not affect the business continuity,” said Krishna Prasad, Chairman and Managing director, Granules India Limited, commenting on the USFDA Audit.
Stock view:
Granules India Ltd is currently trading at Rs175.70, up by Rs0.05 or 0.03% from its previous closing of Rs175.65 on the BSE.
The scrip opened at Rs175.65 and has touched a high and low of Rs179.50 and Rs173.10 respectively.
For Quick Trial – 8871888787
or mail us here - support@researchicon.com
or visit - http://www.researchicon.com/free-trial
Post a Comment